Cabaletta Bio, Inc. (CABA)
After hours:
| Previous Close | 1.8700 |
| Open | 1.9100 |
| Bid | 1.8600 x 500 |
| Ask | 1.9100 x 500 |
| Day's Range | 1.8100 - 2.0100 |
| 52 Week Range | 1.7600 - 26.3500 |
| Volume | |
| Avg. Volume | 1,167,393 |
| Market Cap | 91.4M |
| Beta (5Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1600 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.10 |
GlobeNewswireCabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion
- GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201
